Skip to main content
SpringerLink
Log in

Foam Cell-Derived CXCL14 Muti-Functionally Promotes Atherogenesis and Is a Potent Therapeutic Target in Atherosclerosis

  • Original Article
  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

CXC chemokine family has been related to atherogenesis for long. However, the relationship between CXCL14 and atherogenesis is still unclear. This study preliminarily detected CXCL14 expression at foam cells in atherosclerosis specimens by immunohistochemistry. In vitro foam cells were derived from THP-1 after phorbol-12-myristate-13-acetate (PMA) and oxidized low-density lipoprotein (ox-LDL) stimulation. Immunoblotting and qPCR convinced CXCL14 expression variation during foam cell formation. We further demonstrated that ox-LDL regulated CXCL14 expression by AP-1. AP-1 could bind to CXCL14 promoter and up-regulate CXCL14 mRNA expression. Besides, CXCL14 promoted THP-1 migration, macrophage lipid phagocytosis, and smooth muscle cell migration as well as proliferation mainly via the ERK1/2 pathway. Additionally, a CXCL14 peptide-induced immune therapy showed efficacy in ApoE−/− mouse model. In conclusion, our study demonstrated that CXCL14 is highly up-regulated during foam cell formation and promotes atherogenesis in various ways. CXCL14 may be a potent therapeutic target for atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Ference, B. A., Ginsberg, H. N., Graham, I., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.[J]. European Heart Journal, 38, 2459–2472.

    Article  CAS  Google Scholar 

  2. Cao Dian, J. (2018). Macrophages in cardiovascular homeostasis and disease.[J]. Circulation, 138, 2452–2455.

    Article  CAS  Google Scholar 

  3. Tabas, I., & Lichtman, A. H. (2017). Monocyte-macrophages and T cells in atherosclerosis.[J]. Immunity, 47, 621–634.

    Article  CAS  Google Scholar 

  4. Puca, A. A., Carrizzo, A., Spinelli, C., et al. (2019). Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism.[J]. European Heart Journal published ahead of time.

  5. Li, X., Kemmer, L., Zhang, X., et al. (2018). Anti-inflammatory effects on atherosclerotic lesions induced by CXCR4-directed endoradiotherapy.[J]. Journal of the American College of Cardiology, 72, 122–123.

    Article  Google Scholar 

  6. Sainz, J., & Sata, M. (2007). CXCR4, a key modulator of vascular progenitor cells.[J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 263–265.

    Article  CAS  Google Scholar 

  7. Merckelbach, S., van der Vorst, E. P. C., Kallmayer, M., et al. (2018). Expression and cellular localization of CXCR4 and CXCL12 in human carotid atherosclerotic plaques.[J]. Thrombosis and Haemostasis, 118, 195–206.

    Article  Google Scholar 

  8. Salogni, L., Musso, T., Bosisio, D., et al. Activin A induces dendritic cell migration through the polarized release of CXC chemokine ligands 12 and 14. Blood, 113(23), 5848–5856.

  9. Lu, J., Chatterjee, M., Schmid, H., et al. CXCL14 as an emerging immune and inflammatory modulator. Journal of Inflammation (Lond)., 13, 1.

  10. Sleeman, M. A., Fraser, J. K., Murison, J. G., Kelly, S. L., et al. B cell- and monocyte-activating chemokine (BMAC), a novel non-ELR alphachemokine. International Immunology, 12(5), 677–689.

  11. Frederick, M. J., Henderson, Y., et al. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. The American Journal of Pathology, 156(6), 1937–1950.

  12. Kurth, I., Willimann, K., Schaerli, P., et al. Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. The Journal of Experimental Medicine, 194(6), 855–861.

  13. Ozawa, S., Kato, Y., Komori, R., et al. BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochemical and Biophysical Research Communications, 348(2), 406–412.

  14. Tessema, M., Klinge, D. M., Yingling, C. M., et al. Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene., 29(37), 5159–5170.

  15. Song, E. Y., Shurin, M. R., Tourkova, I. L., et al. Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells. Cancer Research, 70(11), 4394–4401.

  16. Nara, N., Nakayama, Y., Okamoto, S., et al. (2007). Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance.[J]. The Journal of Biological Chemistry, 282, 30794–30803.

    Article  CAS  Google Scholar 

  17. Tanegashima, K., Suzuki, K., Nakayama, Y., et al. (2010). Antibody-assisted enhancement of biological activities of CXCL14 in human monocytic leukemia-derived THP-1 cells and high fat diet-induced obese mice.[J]. Experimental Cell Research, 316, 1263–1270.

    Article  CAS  Google Scholar 

  18. Poon, W.-L., Alenius, H., Ndika, J., et al. (2017). Nano-sized zinc oxide and silver, but not titanium dioxide, induce innate and adaptive immunity and antiviral response in differentiated THP-1 cells.[J]. Nanotoxicology, 11, 936–951.

    Article  CAS  Google Scholar 

  19. Pelicano, H., et al. Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism. Cancer Research, 69(6), 2375–2383.

  20. Foncea, R., Mazière, C., et al. Endothelial cell oxidative stress and signal transduction. Biological Research, 33(2), 89–96.

  21. Suxia, M., Zhifeng, B., et al. The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-κB. European Journal of Pharmacology, 851, 186–193.

  22. Sterner, R. M., Takahashi, P. Y., Yu, B., & Aimee, C. (2016). Active vaccines for Alzheimer disease treatment.[J]. Journal of the American Medical Directors Association, 17, 862.e11–862.e15.

    Article  Google Scholar 

Download references

Funding

This study was supported in part by research grants 81770263, 81570254, and 31271040 from the National Natural Science Foundation of China.

Author information

Authors and Affiliations

  1. Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, People’s Republic of China

    Weilin Tong, Yaqi Duan, Rumeng Yang, Ying Wang, Changqing Peng, Zitian Huo & Guoping Wang

  2. Department of Pathology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, People’s Republic of China

    Weilin Tong, Yaqi Duan, Rumeng Yang, Ying Wang, Changqing Peng, Zitian Huo & Guoping Wang

Authors
  1. Weilin Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yaqi Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rumeng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ying Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Changqing Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zitian Huo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guoping Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

W.T., R.Y., C.P., and Y.W. conducted the experiments. Y.D. analyzed the results. W.T. wrote the manuscript. Z.H. and G.W. conceived the experiments. All authors reviewed the manuscript.

Corresponding authors

Correspondence to Zitian Huo or Guoping Wang.

Ethics declarations

All experimental protocols were approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. All animal studies were performed in accordance with the Guidelines of the Hubei Council of Animal Care and approved by the Experimental Animal Committee of the Huazhong University of Science and Technology in China. The informed consent was obtained from all subjects, and this study is approved by the Ethical Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Competing Interests

The authors declare that they have no competing interests.

Additional information

Associate Editor Nicola Smart oversaw the review of this article.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(JPG 74 kb)

ESM 2

(JPG 196 kb)

ESM 3

(JPG 107 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tong, W., Duan, Y., Yang, R. et al. Foam Cell-Derived CXCL14 Muti-Functionally Promotes Atherogenesis and Is a Potent Therapeutic Target in Atherosclerosis. J. of Cardiovasc. Trans. Res. 13, 215–224 (2020). https://doi.org/10.1007/s12265-019-09915-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-019-09915-z

Keywords

Search

Navigation